Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

• Status: Completed
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Finnish Institute for Health and Welfare; National Institute for Health and Welfare, Finland
• Treatments: Naloxone; Narcotic Antagonists

Criteria

Inclusion Criteria:

• age over 18 years old

• South Oaks Gambling Scale (SOGS) 5 or over points

• possibility to keep a record with phone and send text messages

• fluent in Finnish Language

Exclusion Criteria:

• active drug use (specially opioids) current use - drugs screen

• nasal abnormality or mucosal irritability

• hepatitis c virus, kidney insufficiency

• psychosis, unstable mental health, risk suicide (Beck Depression Inventory)

• pregnancy and/or breast feeding

• persons according to Finnish Medical Law 188/1999 §7-10